Balance between transmitted HLA preadapted and nonassociated polymorphisms is a major determinant of HIV-1 disease progression
File(s)J Exp Med-2016-Mónaco-jem.20151984.pdf (1.62 MB)
Published version
Author(s)
Type
Journal Article
Abstract
HIV-1 adapts to a new host through mutations that facilitate immune escape. Here, we evaluate the impact on viral control and disease progression of transmitted polymorphisms that were either preadapted to or nonassociated with the new host's HLA. In a cohort of 169 Zambian heterosexual transmission pairs, we found that almost one-third of possible HLA-linked target sites in the transmitted virus Gag protein are already adapted, and that this transmitted preadaptation significantly reduced early immune recognition of epitopes. Transmitted preadapted and nonassociated polymorphisms showed opposing effects on set-point VL and the balance between the two was significantly associated with higher set-point VLs in a multivariable model including other risk factors. Transmitted preadaptation was also significantly associated with faster CD4 decline (<350 cells/µl) and this association was stronger after accounting for nonassociated polymorphisms, which were linked with slower CD4 decline. Overall, the relative ratio of the two classes of polymorphisms was found to be the major determinant of CD4 decline in a multivariable model including other risk factors. This study reveals that, even before an immune response is mounted in the new host, the balance of these opposing factors can significantly influence the outcome of HIV-1 infection.
Date Issued
2016-08-22
Date Acceptance
2016-07-25
Citation
Journal of Experimental Medicine, 2016, 213 (10)
ISSN
1540-9538
Publisher
Rockefeller University Press
Journal / Book Title
Journal of Experimental Medicine
Volume
213
Issue
10
Copyright Statement
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
Subjects
Immunology
11 Medical And Health Sciences
Publication Status
Published
Article Number
2049